Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Marius Ardeleanu, Eric L. Simpson et al.|The Lancet|2015Cited by 566
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Amy S. Paller et al.|The Lancet|2021Cited by 538
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, Elaine C. Siegfried et al.|Journal of the American Academy of Dermatology|2020Cited by 385
Psoriasis: a possible risk factor for development of coronary artery calcificationRalf J. Ludwig, Wolf‐Henning Boehncke, C. Herzog et al.|British Journal of Dermatology|2006Cited by 376
Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasisM. Grundmann-Kollmann, Maurizio Podda, Ralf J. Ludwig et al.|Journal of the American Academy of Dermatology|2004Cited by 62